Tolerability of Teclistamab Improved with Step-Up Dosing
In a discussion with Targeted Oncology, David Dingli, MD, PhD, looks at how the use of step-up dosing with tecalistimab helped avoid many serious adverse events.
Future Landscape: Collaboration for Patients With Relapsed/Refractory Multiple Myeloma
Discover how the treatment landscape for relapsed/refractory myeloma is evolving through collaboration between academic centers and community oncologists, offering patients access to innovative therapies and clinical trials.
Navigating Unmet Needs and Challenges in Multiple Myeloma Treatment
Patient-Centered Approach to Managing Bispecific Antibody Therapy
The importance of patient education, remote monitoring, and infection prophylaxis in the safe administration of bispecific antibody therapy for relapsed/refractory multiple myeloma.
Choosing Between CAR T and Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
David M. Dingli, MD, PhD, discusses the advantages and considerations of CAR T-cell therapy versus bispecific antibodies for relapsed/refractory multiple myeloma, helping patients make informed treatment decisions.
Talquetamab and Elranatamab: Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
Insights into the use of bispecific antibodies, including talquetamab, and elranatamab, in treating relapsed/refractory multiple myeloma, discussing their efficacy and potential side effects.
Impact of Teclistamab on the Management of Relapsed/Refractory Multiple Myeloma
Expert perspective on teclistamab, a bispecific antibody, in the context of multiple myeloma treatment, discussing its potential benefits and associated considerations.
Immunologic Therapies in Multiple Myeloma: Expert Insights
An exploration of the landscape of immunologic therapies and alternative approaches for relapsed/refractory multiple myeloma, including bispecific antibodies, XPO1 inhibitors, venetoclax, and more.
Patient Case: A 76-Year-Old Man with Pentarefractory Multiple Myeloma
David M. Dingli, MD, PhD, a hematologist at Mayo Clinic, as he discusses a challenging case of pentarefractory multiple myeloma in a 76-year-old patient and explores novel treatment options.
Dingli Compares Trial Data and Recent ASH Updates in the Newly Diagnosed Multiple Myeloma Landscape
The National Comprehensive Cancer Network considers multiple regimens to be acceptable for transplant-eligible patients with a new diagnosis of multiple myeloma. David Dingli, MD discussed the regimens that are currently available for patients.
2 Clarke Drive Cranbury, NJ 08512